BRAFTOVI — ARRAY BIOPHARMA INC, approved 2026-02-24 (NDA210496).
8,480 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.